Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Summary

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelvir (S-217622), an antiviral, to treat individuals with Long COVID in an adult population.

Timeline

Start

2024-04-09

Primary completion

2024-12-20

Completion

2026-12-31

Drugs

Indications